Posted by Michael Wonder on 11 Aug 2020
Cenobamate designated Promising Innovative Medicine by the UK’s MHRA for treatment of drug-resistant focal-onset seizures in adults
11 August 2020 - PIM designation is an early indication that cenobamate is a promising candidate for the MHRA’s Early Access to Medicine Scheme.
Arvelle Therapeutics today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has informed the company that a Promising Innovative Medicine (PIM) designation has been issued for its investigational anti-seizure medication, cenobamate, for the treatment of drug-resistant focal-onset seizures in adults.
A PIM designation is an early indication that a medicinal product is a promising candidate for the Early Access to Medicines Scheme (EAMS). Launched in 2014, EAMS aims to provide patients in the UK with life threatening or seriously debilitating conditions access to medicines that do not yet have a marketing authorisation when there is a clear unmet medical need.
